title: [Treatment of acute lymphoblastic leukemia in children according to the ALL-BFM-90m protocol in the Russian Federation and the Republic of Belarus].
abstract: Prognosis for children treated according to the BFM-90m protocol (Berlin-Frankfurt-Munster Group) for acute lymphoblastic leukemia (ALL) improved significantly as compared with previous modalities. Methotrexate was used in the dose of 1,000 mg/m2, 36 h. The paper presents the 10-year results for this modification. Patients aged 0-15 years were treated at hematological hospitals of Moscow, other Russian towns and in Minsk, Belarus, (July 5, 1990-November 11, 2000). BFM-90m treatment was given to 682 children out of 1,326 with primary diagnosis of ALL; a comparative trial of the MB-91 protocol hed been carried out at the same clinics since 1991. During 10 years, recurrence-free survival was 72% while overall survival--77%. Toxicity of side-effects was tolerable. The BFM-90m treatment showed significantly better results in both countries.
authors.affiliation: Research Institute of Pediatric Hematology and Oncology, Ministry of Health of the RF, Russian Children's Clinical Hospital, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Miakova
authors.forename: O V
authors.initials: OV
authors.lastname: Aleĭnikova
authors.forename: R
authors.initials: R
authors.lastname: Hartmann
authors.forename: A E
authors.initials: AE
authors.lastname: Rudneva
authors.forename: N M
authors.initials: NM
authors.lastname: Trubina
authors.forename: L G
authors.initials: LG
authors.lastname: Fechina
authors.forename: A M
authors.initials: AM
authors.lastname: Timakov
authors.forename: A V
authors.initials: AV
authors.lastname: Shamardina
authors.forename: V V
authors.initials: VV
authors.lastname: Lebedev
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Varfolomeeva
authors.forename: S D
authors.initials: SD
authors.lastname: Dudkin
authors.forename: Z M
authors.initials: ZM
authors.lastname: Dyshlevaia
authors.forename: V N
authors.initials: VN
authors.lastname: Timofeeva
authors.forename: A G
authors.initials: AG
authors.lastname: Rumiantsev
authors.forename: H
authors.initials: H
authors.lastname: Henze
authors.forename: A I
authors.initials: AI
authors.lastname: Karachunskiĭ
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D002094:Republic of Belarus; D012307:Risk Factors; D012426:Russia; D012737:Sex Factors; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D008727:Methotrexate